Sara Nayeem

Sara Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Sara Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies. She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. In addition, she assists with management of several of NEA's publicly traded portfolio companies. Prior to joining NEA, Sara Nayeem was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age related macular degeneration. Sara Nayeem concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biological Sciences from Harvard University.